NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

文章核心观点 - 一家名为Bragar Eagel & Squire的律师事务所宣布，已代表在2024年3月7日至2025年5月23日期间购买Savara Inc (NASDAQ: SVRA)证券的投资者，对该公司提起集体诉讼 [2] - 诉讼指控Savara公司在上述类别期间内，未能披露其MOLBREEVI生物制剂许可申请的实质性缺陷以及美国食品药品监督管理局不太可能批准该申请的事实，这些未披露的信息对公司股价造成了负面影响 [8] 诉讼案件细节 - 诉讼在美国宾夕法尼亚州东区地方法院提起，投资者申请成为首席原告的截止日期为2025年11月7日 [2] - 指控要点包括：公司未披露MOLBREEVI的BLA申请在化学、制造和控制方面信息不足；因此FDA不太可能以当前形式批准该BLA；公司可能无法按向投资者承诺的时间表完成BLA提交；监管批准延迟增加了公司需要筹集更多资金的可能性 [8] - 2025年5月27日，Savara发布新闻稿宣布收到FDA的拒收函，FDA初步审查认为BLA申请不够完整，无法进行实质性审查，并要求提供更多CMC相关数据 [8] - 此消息导致Savara股价在2025年5月27日下跌0.90美元，跌幅达31.69%，收盘报1.94美元 [8]

集体诉讼案件核心信息 - 律师事务所向在特定期间内购买Savara Inc (NASDAQ: SVRA)股票的股东发出通知 [1] - 集体诉讼期定义为2024年3月4日至2025年5月23日 [1] - 股东登记参与集体诉讼的截止日期为2025年11月7日 [2] 针对公司的指控摘要 - 指控称公司在集体诉讼期间发布了重大虚假和/或误导性陈述，且未能披露相关信息 [1] - 具体指控包括其治疗肺泡蛋白沉积症的MOLBREEVI生物制剂许可申请缺乏关于化学、制造和/或控制的充分信息 [1] - 指控认为因此美国食品药品监督管理局不太可能以当前形式批准该申请，且公司不太可能在其向投资者承诺的时间框架内完成提交 [1] - 指控还指出监管批准的延迟增加了公司需要筹集额外资金的可能性 [1]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading nationa ...

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete submission of the MO ...

Accessibility StatementSkip Navigation The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by th ...

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

LOS ANGELES, Oct. 1, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE BEFORE NOVEMBER 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between March 7, 2024 and May 23, 2025, Defendants fa ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...